SOURCE: Q Therapeutics, Inc.
SALT LAKE CITY, UT--(Marketwire - Oct 25, 2012) - Q Holdings, Inc., dba Q Therapeutics, Inc., an emerging biotechnology company utilizing its proprietary innovative technology to develop breakthrough cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, will be presenting at the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum -- a premier business development and partnering meeting for regenerative medicine companies.
The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine (CIRM) to profile the industry's most exciting technologies. Thirty-five companies and organizations will be presenting over the course of two days, ranging from translational research centers to emerging-growth biotech companies, as well as established, publicly traded industry leaders.
The following are specific details regarding Q Therapeutics' presentation at the conference:
October 29, 2012
10:15 AM PDT
Sanford Consortium for Regenerative Medicine Building
Auditorium, Second Floor Terrace
2880 Torrey Pines Scenic Drive
La Jolla, California
The Investor and Partnering Forum was created in 2011 to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. It will be held immediately prior to the Stem Cell Meeting on the Mesa's Scientific Symposium organized by the Sanford Consortium, and the combined meetings are expected to attract over 800 attendees from around the globe. The company presentations will be recorded by ARM and will be made available on ARM's website shortly after the event. To learn more or to register for the 2012 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com. Registration is required.
About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Holdings, Inc., dba Q Therapeutics, Inc., is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal function of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND filing expected in 2013. For more information, visit www.qthera.com.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Q Therapeutics' technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of its intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Q Therapeutics' periodic reports, including the quarterly report on Form 10-Q for the period ended June 30, 2012.